Researchers Solve the Puzzle of a Brain Receptor’s Activation

June 20, 2023 • Research Highlight G protein-coupled receptors (also called metabotropic receptors) are specific locations on the surface of nerve cells, or neurons, that help cells communicate with each other. These receptors are activated when signaling molecules bind to them. However, for some G protein-coupled receptors, no molecule capable of turning on their signaling…

Read More

Where There’s Not a Will: The Covenant Theology of Hebrews 9

ABSTRACT: Most English Bibles translate diathēkē as “covenant” throughout Hebrews — except in Hebrews 9:16–17, where they read “will.” Though good reasons lie behind the use of “will,” better evidence weighs in favor of “covenant.” Not only does the near and wider context of Hebrews make “will” unlikely, but the particular wording of the passage,…

Read More

Sleep Issues Persist in Adolescent Rats After Alcohol Withdrawal, Highlighting Teen Drinking Risks

Adolescent rats exposed to alcohol vapor experience persistent sleep disruption after withdrawal, as measured by Fitbit-like tracking devices, providing insight into the relationship between sleep disturbance and heavy drinking in humans, according to a new study published in Alcohol: Clinical & Experimental Research. Although adolescents and young adults may be particularly affected by sleep disturbances…

Read More

The Pastor as Wizard

Gandalf is beloved by many, and for good reason. J.R.R. Tolkien’s wizard is a noble picture of wisdom and strength in the face of great evil. It’s hard not to like him. In Gandalf, Tolkien sets forth the wizard in his most positive and righteous light. This positive light has been captured recently in a…

Read More

Incannex Enlists Investigators for Phase 2/3 Study of IHL-42X for Sleep Apnea

Incannex Healthcare Ltd, a clinical-stage pharmaceutical company developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies, has recruited two lead principal investigators for the Investigational New Drug opening phase 2/3 clinical trial investigating IHL-42X, a cannabinoid combination product, for the treatment of obstructive sleep apnea (OSA).  John D. Hudson, MD, principal investigator for FutureSearch Trials…

Read More